share_log

Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $2

Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $2

Ascendiant Capital維持對Outlook Therapeutics的買入,將目標股價
Benzinga ·  2023/12/29 06:47

Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $1.5 to $2.

Ascendiant Capital分析師愛德華·胡維持Outlook Therapeutics(納斯達克股票代碼:OTLK)的買入並將目標股價從1.5美元上調至2美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論